A key innovation is the Adaptive Basal-Bolus Advisor (ABBA), a self-learning system that adapts insulin recommendations multiple times per day. It is designed to operate across real-world settings, supporting continuous glucose monitoring, self-monitoring of blood glucose, flash glucose monitoring, as well as both insulin pens and pumps. The approach has been extensively validated in silico, with feasibility demonstrated for insulin-pen users, and is currently being evaluated in a multicentre clinical study.
Together, these efforts aim to shift diabetes care from reactive to proactive management while reducing daily burden.
This research is supported by the SANITAS Foundation, the European Commission, and the Swiss State Secretariat for Education, Research and Innovation (SERI) through the MELISSA project (Grant 101057730).
